Pfizer said Elrexfio met the main goal in a late-stage trial in patients who had received at least one prior line of treatment. The result is a positive clinical milestone for the blood cancer therapy and supports its development trajectory. The news is constructive for Pfizer but limited to a single program, so likely market impact is modest.
Pfizer said Elrexfio met the main goal in a late-stage trial in patients who had received at least one prior line of treatment. The result is a positive clinical milestone for the blood cancer therapy and supports its development trajectory. The news is constructive for Pfizer but limited to a single program, so likely market impact is modest.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
